***السيرة الذاتية***

**الاسم : أ.د.عبير أنور أحمد**

***الجامعة المستنصرية – كلية-الطب--***

***Mobile: +9647804056861***

***Email:* abeeranwerahmed@gmail.com**

**ملخص تعريفي:استاذ علم امراض الدم و طبيب استشاري**

 **شغلت منصب مدير المركز الوطني لبحوث و علاج أمراض الدم و مدير عام المركز العراقي لبحوث السرطان و الوراثة الطبية.**

**اشرفت على العديد من طلبة المجلس العراقي للاختصاصات الطبية و طلبة الماجستير**

* **كلمات مختصرة وليس فقرات مختصرة اضافة الى بعض الخبرات المهنية.**

**الشهادات الدراسية:**

* **البورد العراقي في علم امراض الدم**
* **بكلوريوس طب و جراحة عامة**

**الجوائز والتكريم الأكاديمي**

* **#1:**
* **#2:**

**الخبرة الأكاديمية والتدريس:**

* **تدريس الدراسات الاولية لعلم امراض الدم**
* **تدريس طلبة الدراسات العليا الماجستير و الدكتوراة**
* **تدريس طلبة المجلس العراقي للاختصاصات الطبية -البورد**

**المقررات الدراسية التي تم تدريسها:**

|  |  |
| --- | --- |
| **الدراسات الأولية** | **الدراسات العليا** |
| **امراض الدم للمرحلة الثالثة****المختبرات السريري للمرحلة الخامسة** | **ماجستير امراض دم****و دكتوراة الكيمياء الحياتية** |

**الأنتساب المهني او الجمعيات**

* **مدير عام المركز العراقي لبحوث السرطان و الوراثة الطبية**
* **مدير المركز الوطني لبحوث و علاج امراض الدم**
* **مقرر الدراسات العليا في فرع الامراض و الطب العدلي**
* **عضو فريق المقيمين الوطنيين**
* **رئيس لجنة المقاصة العلمية**
* **عضو اللجنة العلمية**
* **عضو نقابة الاطباء**
* **عضو جمعية امراض الدم**

**المنشورات العلمية**

* **بحوث علمية.**

**1-**[**Imatinib Mesylate Related Immunolological Changes in Chronic Myeloid Leukemia**](https://www.researchgate.net/profile/Abeer-Anwer/publication/332738511_Imatinib_Mesylate_Related_Immunolological_Changes_in_Chronic_Myeloid_Leukemia/links/5cc7444ea6fdcc1d49b97fe1/Imatinib-Mesylate-Related-Immunolological-Changes-in-Chronic-Myeloid-Leukemia.pdf)

**2- Neutrophils phagocytic function in chronic myelogenous leukemia after imatinib mesylate therapy**

**3- Biomarkers and trace elements in beta thalassemia major**

**4-**[**Platelet indices and their relations to platelet count in hypo-productive and hyper-destructive Thrombocytopenia**](https://iraqjournals.com/article_98300_712413b1b79a2d9077c369dc494a0e87.pdf)

**5-**[**Mean platelet volume, platelet distribution width and plateletcrit values in differentiating clonal from secondary thrombocytosis**](https://www.iasj.net/iasj/article/75626)

**6- Potential effect of Imatinib on some sex hormones for male patients of Chronic Myelogenous Leukemia in Baghdad province**

**7- Chronic Myeloid Leukemia: A retrospective study of clinical and pathological features**

**8- ASSESSMENT OF SOME HEMATOLOGICAL AND BIOCHEMICAL PARAMETERS FOR COVID-19 PATIENT’S IN BAGHDAD PROVINCE**

**9- POLYMORPHISM OF TET2 GENE AMONG IRAQI ACUTE MYELOID LEUKEMIA**

**10- The significance of serum hepcidin on iron status in overweight and obese patients with iron‑deficiency anemia**

**11- Potential effect of Imatinib on some sex hormones for male patients of Chronic Myelogenous Leukemia in Baghdad province**

**12- Evaluation of serum level of lymphoid enhancer‑binding factor‑1 and its relation with clinico‑hematological and prognostic parameters in pediatric patients with acute lymphoblastic**

**leukemia**

**13- Comparison between H63D and G71D**

**gene mutation effects on iron overload**

**in Iraqi patients with β‑thalassemia**

**major: A case–control study**

**14- ASSESSMENT OF MALONDIALDEHYDE AND GLUTATHIONE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED BY IMATINIB**

**15- The effect of NSAIDS and oral hypoglycemic agent on Leukemia and lymphoma cell lines**

**16-** [**DNMT3A Gene Polymorphismin Iraqi Acute Myeloid Leukemia Patients and its Relation to Prognostic Factors and Response to Therapy**](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=6LKQyNcAAAAJ&citation_for_view=6LKQyNcAAAAJ:5nxA0vEk-isC)

**17-** [**Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Gene Polymorphism And Treatment Outcome Following Imatinib Therapy In Iraqi Patients With Chronic Myeloid Leukemia**](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=6LKQyNcAAAAJ&citation_for_view=6LKQyNcAAAAJ:hqOjcs7Dif8C)

**18-** [**Evaluation of interleukin‑35 and interleukin‑10 in adult acute myeloid leukemia patients before and after induction chemotherapy**](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=6LKQyNcAAAAJ&citation_for_view=6LKQyNcAAAAJ:YsMSGLbcyi4C)

**19-** [**Growth‑differentiation factor‑15 expression in anemia of chronic disease and iron‑deficiency anemia**](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=6LKQyNcAAAAJ&citation_for_view=6LKQyNcAAAAJ:W7OEmFMy1HYC)

**20-** [**Immunohistochemical Expression of CD26 in Bone Marrow Biopsies of Chronic Lymphocytic Leukemia Patients**](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=6LKQyNcAAAAJ&citation_for_view=6LKQyNcAAAAJ:IjCSPb-OGe4C)

**21-** [**Assessment of complement regulatory proteins CD35 and CD55 in β-thalassemia patients**](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=6LKQyNcAAAAJ&citation_for_view=6LKQyNcAAAAJ:roLk4NBRz8UC)

**22- Immunohistochemical Expression of CD27 in Bone Marrow Biopsies of Chronic Lymphocytic Leukemia Patients**

**23-Chronic Myeloid Leukemia: A retrospective study of clinical and patho- logical features**

**تطوير المهارات:**

* **المؤتمرات**

**رئيس المؤتمر التاسع للمركز الوطني لبحوث و علاج امراض الدم**

**عضو اللجنة العلمية لمؤتمر الفيزياء الطبية الدولي**

**عضو اللجنة العلمية لمؤتمر دراسات المرأة الثاني**

* **الورش و الندوات**

**المستجدات في مرض فقر دم البحر المتوسط**

**فقر الدم المنجلي**

**نفص انزيم G6PD**

**التغيرات الجزيئية في مرض ابيضاض الدم**

**امراض الدم المنتقلة عبر الكروموسوم X**

**الخلايا الجذعية السرطانية**

**الهيموفيليا**

***Curriculum Vitae***

**Name: professor Abeer Anwer Ahmed**

***Mustansiriyah University – College of medicine***

***Mobile: +9647804056861***

***Email:*** ***username@email.com***

**Personal Summary:**

**Professor in hematology, consultant DACTOR**

**Worked a manager of the national center of hematology and general manager of the Iraqi center of cancer and medical genetics researches .**

**Supervisor of the students of THE Iraqi board for medical specialization**

* **Short words not short paragraph please. With some Professionals.**

**Education:**

* **F.I.C.M.S hematology**
* **M..B.Ch.B**

**ACADEMIC HONORS AND AWARDS:**

**ACADEMIC /TEACHING EXPERIENCE:**

* **Undergrduate teaching**
* **Postgraduate (MCs and PhD)**

**COURSES TAUGHT:**

|  |  |
| --- | --- |
| **Undergraduate** | **Graduate** |
| **3ed year hematology****5th year clinical lab.** | **MSc hematology****PhD biochemistry****Iraqi board of medical specialization**  |

**PROFESSIONAL AFFILIATIONS:**

**Director General of the Iraqi Center for Cancer and Medical Genetics Researches**

**Director of the National Center of hematology**

**Postgraduate director in pathology and forensic medicine department**

**Member of the National assessor Team**

**Chairman of the Scientific Clearing Committee**

**Member of the Scientific Committee**

**Member of the Medical Syndicate**

**Member of hematology Society**

**PUPLICATIONS:**

* **Papers.**

**1-**[**Imatinib Mesylate Related Immunolological Changes in Chronic Myeloid Leukemia**](https://www.researchgate.net/profile/Abeer-Anwer/publication/332738511_Imatinib_Mesylate_Related_Immunolological_Changes_in_Chronic_Myeloid_Leukemia/links/5cc7444ea6fdcc1d49b97fe1/Imatinib-Mesylate-Related-Immunolological-Changes-in-Chronic-Myeloid-Leukemia.pdf)

**2- Neutrophils phagocytic function in chronic myelogenous leukemia after imatinib mesylate therapy**

**3- Biomarkers and trace elements in beta thalassemia major**

**4-**[**Platelet indices and their relations to platelet count in hypo-productive and hyper-destructive Thrombocytopenia**](https://iraqjournals.com/article_98300_712413b1b79a2d9077c369dc494a0e87.pdf)

**5-**[**Mean platelet volume, platelet distribution width and plateletcrit values in differentiating clonal from secondary thrombocytosis**](https://www.iasj.net/iasj/article/75626)

**6- Potential effect of Imatinib on some sex hormones for male patients of Chronic Myelogenous Leukemia in Baghdad province**

**7- Chronic Myeloid Leukemia: A retrospective study of clinical and pathological features**

**8- ASSESSMENT OF SOME HEMATOLOGICAL AND BIOCHEMICAL PARAMETERS FOR COVID-19 PATIENT’S IN BAGHDAD PROVINCE**

**9- POLYMORPHISM OF TET2 GENE AMONG IRAQI ACUTE MYELOID LEUKEMIA**

**10- The significance of serum hepcidin on iron status in overweight and obese patients with iron‑deficiency anemia**

**11- Potential effect of Imatinib on some sex hormones for male patients of Chronic Myelogenous Leukemia in Baghdad province**

**12- Evaluation of serum level of lymphoid enhancer‑binding factor‑1 and its relation with clinico‑hematological and prognostic parameters in pediatric patients with acute lymphoblastic**

**leukemia**

**13- Comparison between H63D and G71D**

**gene mutation effects on iron overload**

**in Iraqi patients with β‑thalassemia**

**major: A case–control study**

**14- ASSESSMENT OF MALONDIALDEHYDE AND GLUTATHIONE IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED BY IMATINIB**

**15- The effect of NSAIDS and oral hypoglycemic agent on Leukemia and lymphoma cell lines**

**16-** [**DNMT3A Gene Polymorphismin Iraqi Acute Myeloid Leukemia Patients and its Relation to Prognostic Factors and Response to Therapy**](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=6LKQyNcAAAAJ&citation_for_view=6LKQyNcAAAAJ:5nxA0vEk-isC)

**17-** [**Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Gene Polymorphism And Treatment Outcome Following Imatinib Therapy In Iraqi Patients With Chronic Myeloid Leukemia**](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=6LKQyNcAAAAJ&citation_for_view=6LKQyNcAAAAJ:hqOjcs7Dif8C)

**18-** [**Evaluation of interleukin‑35 and interleukin‑10 in adult acute myeloid leukemia patients before and after induction chemotherapy**](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=6LKQyNcAAAAJ&citation_for_view=6LKQyNcAAAAJ:YsMSGLbcyi4C)

**19-** [**Growth‑differentiation factor‑15 expression in anemia of chronic disease and iron‑deficiency anemia**](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=6LKQyNcAAAAJ&citation_for_view=6LKQyNcAAAAJ:W7OEmFMy1HYC)

**20-** [**Immunohistochemical Expression of CD26 in Bone Marrow Biopsies of Chronic Lymphocytic Leukemia Patients**](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=6LKQyNcAAAAJ&citation_for_view=6LKQyNcAAAAJ:IjCSPb-OGe4C)

**21-** [**Assessment of complement regulatory proteins CD35 and CD55 in β-thalassemia patients**](https://scholar.google.com/citations?view_op=view_citation&hl=en&user=6LKQyNcAAAAJ&citation_for_view=6LKQyNcAAAAJ:roLk4NBRz8UC)

**22- Immunohistochemical Expression of CD27 in Bone Marrow Biopsies of Chronic Lymphocytic Leukemia Patients**

**23-Chronic Myeloid Leukemia: A retrospective study of clinical and patho- logical features**

**PROFFESSIONAL DEVELOPMENT**

* **Conferences.**

**Chairman of the 9th conference of the national center of hematology**

**Member of scientific committee of the international conference of medical physics**

**Member of scientific committee of the 2nd conference of Women's Studies Center**

* **Workshops.**

**Update in thalassemia**

**Sickle cell anemia**

**G6PD deficiency**

**Molecular changes in leukemia**

**X linked hematological diseses**

**Cancer stem cells**

**hemophilia**